- Home
- MOLN vs SCPH Comparison
MOLN vs SCPH Comparison
Compare MOLN & SCPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOLN
- SCPH
- Stock Information
- Founded
- MOLN 2004
- SCPH 2013
- Country
- MOLN Switzerland
- SCPH United States
- Employees
- MOLN N/A
- SCPH N/A
- Industry
- MOLN
- SCPH Biotechnology: Pharmaceutical Preparations
- Sector
- MOLN
- SCPH Health Care
- Exchange
- MOLN Nasdaq
- SCPH Nasdaq
- Market Cap
- MOLN 142.6M
- SCPH 299.0M
- IPO Year
- MOLN 2021
- SCPH 2017
- Fundamental
- Price
- MOLN $3.72
- SCPH $5.63
- Analyst Decision
- MOLN Hold
- SCPH Buy
- Analyst Count
- MOLN 1
- SCPH 3
- Target Price
- MOLN $4.00
- SCPH $12.00
- AVG Volume (30 Days)
- MOLN 5.2K
- SCPH 2.3M
- Earning Date
- MOLN 11-05-2025
- SCPH 11-12-2025
- Dividend Yield
- MOLN N/A
- SCPH N/A
- EPS Growth
- MOLN N/A
- SCPH N/A
- EPS
- MOLN N/A
- SCPH N/A
- Revenue
- MOLN $856,302.00
- SCPH $49,969,000.00
- Revenue This Year
- MOLN N/A
- SCPH $108.95
- Revenue Next Year
- MOLN $1,000.00
- SCPH $78.30
- P/E Ratio
- MOLN N/A
- SCPH N/A
- Revenue Growth
- MOLN N/A
- SCPH 107.79
- 52 Week Low
- MOLN $3.36
- SCPH $1.94
- 52 Week High
- MOLN $7.60
- SCPH $6.28
- Technical
- Relative Strength Index (RSI)
- MOLN 50.93
- SCPH 64.37
- Support Level
- MOLN $3.69
- SCPH $4.33
- Resistance Level
- MOLN $3.85
- SCPH $5.62
- Average True Range (ATR)
- MOLN 0.21
- SCPH 0.05
- MACD
- MOLN 0.01
- SCPH 0.01
- Stochastic Oscillator
- MOLN 14.29
- SCPH 93.75
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs. The company's main product is Furoscix to treat congestion in patients with heart failure and edema in patients with chronic kidney disease. Furoscix is a novel formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self-administered subcutaneously via a single-use, disposable, and wearable on-body delivery system.